BRCA1/2 and Effect of Mifepristone on the Breast

只有注册用户可以翻译文章

登陆注册

链接已保存到剪贴板

状态招聘中

赞助商

Karolinska Institutet

临床试验: NCT01898312

BioSeek: nct01898312

关键词

抽象

Ovarian steroids, as well as their synthetic counterparts gestagens and estrogens have a role in breast cell proliferation and the development of breast cancer. Here, the effect of a progesterone receptor modulator, mifepristone, on cell proliferation in human breast tissue in vivo will be studied in women with BRCA-1 or -2 mutations. Our preliminary results implicate a possible protective effect of mifepristone in breast epithelium. The ability of mifepristone to block breast epithelial cell proliferation may prevent tumorigenesis and may also prove beneficial when used for contraceptive purposes and on other indications. The proposed project concerns a Randomized Controlled Trial on mifepristone versus placebo treatment of women with BRCA-1or -2 mutations with a high risk/incidence of breast cancer and ovarian cancer.

描述

Objectives • Research objective To study the safety and effect of treatment with mifepristone, a progesterone receptor modulator, on epithelial cell proliferation in human breast tissue in women with BRCA-1 or -2 mutations prior to protective mastectomy.

Project description

• Hypothesis/ Theory Mifepristone treatment exerts an antiproliferative, protective effect on breast tissue in women with BRCA-1 or -2 mutations

Study Design Randomized, double blind, placebo controlled trial. Women will be recruited among patients with BRCA-1 or -2 mutations scheduled for prophylactic mastectomy. Included women will be randomized to a 3-month treatment with mifepristone, 50 mg (Mifegyne, Exelgyn, Paris, France) or placebo taken orally every second day. Breast biopsies will be obtained in the luteal phase prior to start of treatment and again during surgery.

日期

最后验证:	02/29/2020
首次提交:	07/04/2013
提交的预估入学人数:	07/09/2013
首次发布:	07/11/2013
上次提交的更新:	03/19/2020
最近更新发布:	03/22/2020
实际学习开始日期:	08/31/2013
预计主要完成日期:	11/30/2020
预计完成日期:	03/31/2021

状况或疾病

Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2

干预/治疗

Drug: Mifepristone

相

相 2

手臂组

臂	干预/治疗
Experimental: Mifepristone treatment with oral mifepristone 50 mg every second day for 12 weeks in 30 women with BRCA 1 or 2 mutation
Placebo Comparator: TrioBe treatment with a quarter of a tablet of TrioBe every second day for 12 weeks

资格标准

有资格学习的年龄	18 Years 至 18 Years
有资格学习的性别	Female
接受健康志愿者	是
标准	Inclusion criteria: - Pre-menopausal women, >/= 18 years of age - with good general health and - regular menstrual cycles (25-35 days) who are willing and - able to participate after giving informed consent. - women having BRCA1/2 mutation and have decided to undergo risk reducing mastectomy Exclusion criteria includes: - Any hormonal treatment used within 2 months prior to study start and - Any contraindication to mifepristone

结果

主要结果指标

1. epithelial cell proliferation in breast tissue [3 months]

Changes from baseline after 12 weeks of mifepristone treatment in epithelial cell proliferation by measuring expression of genes specifically in the pathways involving apoptotic and cell proliferation by microarray study, including PTEN, Bcl-2 and Ki-67 along with steroid receptors.

次要成果指标

1. Vital signs and safety lab analysis [3 months]

Safety data includes vital signs, general- and gynecological-, incl breast - examinations, safety lab (hematology (blood status+CRP), kidney function (Na, K, krea) liver function (ASAT, ALAT, ALP, GT, bilirubin) , thyroid function (TSH,T3,T4), hormonal values FSH ,LH , PRL, SHBG, testosterone, E2 (sensitive) progesterone, urine dipstick and pregnancy test (prior to start). Endometrial histology will be investigated in biopsies obtained at baseline and at surgery. Women with BRCA-1/-2 mutations are followed according to the existing clinical routine with regard to ovarian cancer screening.

2. Side effects and Adverse Events [3 months]

Side effects of mifepristone are mild and the only significant side effect reported in previous clinical trials with the same regimen has been mild flushes. All side effects and SAE/AE as well as any concomitant medication will be recoded by the participating patients in a dairy.

3. Endometrial effects [3 months]

Bleeding patterns and endometrial morphologywill be studied. Endometrial histology and progesterone receptor modulator associated changes will be investigated in biopsies obtained at baseline and at surgery. Bleeding pattern will be registered during the study period by the participating women.

4. Ovarian effects [3 months]

Women with BRCA-1/-2 mutations are followed according to the existing clinical routine with regard to ovarian cancer screening.

5. Breast symptom evaluation [3months]

Breast symptom evaluation will be registered at baseline and during the study by a breast symptom score.

BRCA1/2 and Effect of Mifepristone on the Breast

关键词

progesterone

breast neoplasms

ovarian neoplasms

neoplasms

抽象

描述

日期

状况或疾病

干预/治疗

相

手臂组

资格标准

结果

科学支持的最完整的草药数据库